Navigation Links
Tourette Patients Benefit From Behavioral Therapy: Study
Date:8/6/2012

By Alan Mozes
HealthDay Reporter

MONDAY, Aug. 6 (HealthDay News) -- Tourette Syndrome patients fare better when offered tic management therapy as opposed to support sessions solely focused on providing information about the neurological disorder, new research suggests.

The finding is based on a study of 122 patients between the ages of 16 and 55, all of whom struggle with the sudden and unwanted repetitive physical and verbal tics that characterize Tourette Syndrome.

"Typically, medication has been used to treat tics," explained study author Sabine Wilhelm, director of the OCD (obsessive-compulsive disorder) and Related Disorders Program at Massachusetts General Hospital/Harvard Medical School in Boston. "But many patients refuse or discontinue medications due to unwanted side effects."

"Behavior therapy," Wilhelm said, "takes a different approach from medication. Patients often report a premonitory urge -- that's an unpleasant sensation -- prior to engaging in the tic, and they engage in tics in order to relieve the urge. Behavior therapy helps patients to disrupt this pattern. In behavior therapy, patients learn to detect signs that a tic will likely occur and they are taught to engage in competing responses, which are behaviors that are physically incompatible with the impending tic. Thus, patients learn new ways to manage their tics."

"We tested a newer behavioral treatment for tics called Comprehensive Behavioral Intervention for Tics (CBIT)," she said. It "teaches patients to consider the impact of their environment on tics and incorporates procedures to reduce environmental influences that increase tics. The result of our study is exciting news for patients with tic disorders as they now have solid support for behavior therapy for tics."

Wilhelm and her colleagues from several other institutions (including Yale University and the University of Texas Health Science Center at San Antonio) report their findings in the August issue of the Archives of General Psychiatry. The research was supported by the U.S. National Institute of Mental Health.

Tourette syndrome is typified by a wide range of physical and verbal symptoms, which can include uncontrolled eye blinking, head-jerking, reaching out, touching, throat clearing, coughing, and at times the utterance or display of words, phrases, or movements that may involve cursing or the demonstration of socially inappropriate gestures.

However, Wilhelm stressed that to a large degree the public's popular notion of what constitutes Tourette syndrome is off-base, given that four-letter word declarations occur in only about 10 to 15 percent of Tourette patients.

That said, while Tourette syndrome often starts in early childhood and peaks by adolescence, the disorder continues to impair the quality of life of an estimated one in every 2,000 adults, for whom medication may prove problematic.

Between 2005 and 2009, Wilhelm's team focused on Tourette syndrome -- as well as chronic tic disorder -- in patients being treated at one of three outpatient research clinics.

For a 10-week period, roughly half the patients were offered eight sessions of standard patient support and education, which provided information concerning both the neurological underpinnings of the disorder and the range of effects and possible treatments.

The other half was given eight sessions of the comprehensive behavioral intervention, which focused on tic awareness to help patients detect early warning signs of an imminent tic; relaxation training; and so-called "competing-response training." This training teaches patients how to voluntarily engage in behaviors that might impede the onset of tics -- such as breathing rhythmically to block word bursts, or pressing the elbow into the torso to prevent arm thrusts. They also talked about management of situations that might raise the risk for experiencing a tic.

Patients in either group who were already on medications before the study launch continued to take them throughout.

Mental health evaluations revealed that more than 38 percent of those in the intervention group showed "significant" improvement, a figure that dropped to just about 7 percent among the support/education group.

Specifically, tic severity dropped by 26 percent among the behavioral intervention patients, but only by about 12 percent among the other group.

Follow-up testing further showed that behavioral-intervention patients who did derive benefit maintained their symptom improvement six months down the road.

"The obvious next step," Wilhelm said, "is to teach clinicians how to administer CBIT."

More information

For more on Tourette syndrome and therapy, visit the National Tourette Syndrome Association.

SOURCES: Sabine Wilhelm, Ph.D., director, OCD and Related Disorders Program, Massachusetts General Hospital/Harvard Medical School, Boston; August 2012 Archives of General Psychiatry


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Moffitt Cancer Center researcher & colleagues test new drug for patients with neuroendocrine tumors
2. Off-label drug use common, but patients may not know theyre taking them, Mayo finds
3. Trauma Patients at Higher Risk of Dying of Hypothermia: Study
4. Virtual Patients New Addition to Psychiatry?
5. New study suggests clinicians overlook alcohol problems if patients are not intoxicated
6. Genes May Be Key for Patients With Multiple Colon Polyps
7. Imaging Tests Up Among Advanced Cancer Patients
8. New Guidelines Say No to Screening EKGs for Low-Risk Patients
9. Diagnostic imaging increases among stage IV cancer patients on Medicare
10. Most Prostate Cancer Patients Dont Die From the Disease: Study
11. Breakthrough treatment reduces post-surgical scarring for glaucoma patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Tourette Patients Benefit From Behavioral Therapy: Study
(Date:4/25/2017)... KY (PRWEB) , ... April 25, 2017 , ... ... announce they have signed an agreement to be the preferred physical therapy provider ... injuries and returning them to Derby City CrossFit as quickly and effectively as ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... compare student test score performance for the 2015-16 school year across Wisconsin’s public ... programs. Though it highlights important patterns in student test score performance, the report’s ...
(Date:4/25/2017)... ... 25, 2017 , ... As pharmaceutical companies are held to ... process innovation in drug formulation and manufacturing. CoreRx offers its clients more ... in support of their development and manufacturing goals. , The company was ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the ... or chronic problems, I focus on preventative care with all my patients to alleviate possible ... questions, always feel free to contact my office and my trained staff will assist you ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® , a ... UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event ... the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal repair ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 NeuroVive ... ("NeuroVive") today announced positive preclinical results demonstrating ... compound for non-alcoholic steatohepatitis (NASH), in an ... NV556 has previously shown similar ... model. Today, NeuroVive,s scientists present novel data ...
(Date:4/19/2017)... April 19, 2017  IRIDEX Corporation (Nasdaq: ... results for the first quarter 2017 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, Inc. ... clinical-stage biopharmaceutical company developing new treatments for cancer ... closing of its previously announced underwritten public offering ... a public offering price of $2.00 per share, ... offering expenses payable by Sorrento.  The net proceeds ...
Breaking Medicine Technology: